Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor

FDA nod to priority review to AstraZeneca’s Baxdrostat for hard-to-control hypertension

Here's a development that aims to keep your blood pressure in check. Literally!

Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients

LYMPHIR addresses a clear clinical need in a disease with limited treatment options

Belite Bio reports landmark phase 3 success for Stargardt Disease therapy

Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging

Lilly slashes prices on Zepbound vials to expanding access to obesity treatment

Patients can now get the starting 2.5 mg dose for $299 per month

Bayer welcomes US Solicitor General’s support as Supreme Court weighs Roundup case

At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits

Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis

Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials

Sudapack breaks ground on major PharmaGuard expansion in Erolzheim

Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production

SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate